● In Stock
CJC-1295
≥99% Purity | HPLC Verified
$45.00
PASSED
Sterility & Endotoxins
PASSED
Net Content & Purity
Purity:
≥99%
Store at
-20°C
Modified GRF(1-29) GHRH analog studied for pulsatile growth hormone release in preclinical research. Research use only.
Research Use OnlyNot for human or veterinary use. For in vitro laboratory research only.
| Strength | 5mg |
| molecular_formula | C152H252N44O42 |
| Molecular Weight | 3367.97 g/mol |
| Purity | >99% (HPLC) |
| Form | Lyophilized Powder |
~30 min
Plasma Half-Life
vs 7 min for native GHRH(1-44)
29 AA
Modified GRF(1-29)
4 amino acid substitutions for protease resistance
~3×
GH Pulse Amplitude
Enhanced GH pulse above baseline
99%+
Purity Verified
HPLC tested, COA included
How CJC-1295 Works
Modified GRF(1-29) — protease-resistant GHRH analog engineered for pulsatile GH stimulation
GHRH-R Agonist
GHRH Receptor Activation
CJC-1295 (without DAC) is a synthetic analog of GHRH(1-29) with four amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to DPP-IV and other plasma proteases. It binds and activates GHRH receptors on pituitary somatotrophs with high affinity, mimicking the action of endogenous GHRH.
- Selective GHRH receptor (GHRH-R) agonism
- DPP-IV resistance via Ala→Aib substitution at position 2
- High-affinity pituitary somatotroph binding
Pulsatile GH
Pulsatile GH Secretion
Unlike CJC-1295 DAC, the no-DAC version has a ~30-minute half-life, producing discrete GH pulses rather than sustained elevation. This pulsatile pattern closely mirrors physiological GH secretion, which occurs in 6–12 pulses per day. Research protocols utilize this property to study natural GH pulse dynamics.
- ~30-minute half-life without albumin binding
- Produces discrete, physiologic GH pulses
- Peak GH response within 15–30 minutes
IGF-1 Axis
GH/IGF-1 Axis Stimulation
Each GH pulse drives transient hepatic IGF-1 production. Unlike the prolonged IGF-1 elevation seen with CJC-1295 DAC, the no-DAC version produces IGF-1 responses timed to each injection, allowing more controlled study of GH pulse-to-IGF-1 relationships in research protocols.
- Transient IGF-1 elevation per GH pulse
- No cortisol or prolactin elevation
- Synergistic with GH secretagogues (e.g., ipamorelin)
What Research Has Shown
Key pharmacological findings from preclinical and pharmacokinetic studies
⚠️ RESEARCH NOTE
CJC-1295 without DAC (Modified GRF 1-29) is a research compound with pharmacological data from preclinical studies and its structurally related DAC-version human trials (Teichman 2006). No standalone Phase 3 human trials have been completed for the no-DAC form. Data should not be extrapolated to therapeutic use.
Research Applications
Primary areas of preclinical and pharmacological investigation
Endocrinology
Pulsatile GH Research
Short half-life makes CJC-1295 no-DAC the preferred GHRH analog for studying discrete GH pulse dynamics — allowing researchers to precisely time and measure individual GH pulses.
Pharmacology
GHRH Analog Comparison
Used as a reference standard in comparative studies evaluating GHRH analog pharmacokinetics, receptor binding, and downstream GH/IGF-1 axis responses versus native GHRH and DAC-modified variants.
Combination Research
CJC / Ipamorelin Synergy
GHRH-R (CJC-1295) and GHSR-1a (ipamorelin) act on complementary pituitary pathways. Combined protocols are studied for additive GH pulse amplitude without cortisol or prolactin co-elevation.
Animal Models
GHRH Axis Restoration
Modified GRF(1-29) used in GHRH-deficient and age-related GH decline animal models to study GHRH receptor replacement activity and GH secretory capacity restoration.
Safety Profile from Research
Preclinical and analogous clinical pharmacological safety data
✓Selective GHRH receptor agonism — cortisol, thyroid hormones, and prolactin are unaffected based on the closely related DAC-form clinical trial data (Teichman et al. JCEM 2006).
✓Short half-life (~30 min) creates a self-limiting pharmacological profile — activity is rapidly cleared without prolonged systemic exposure.
✓Four strategic amino acid substitutions improve stability without introducing off-target receptor interactions in preclinical assay data.
✓No evidence of receptor desensitization or tachyphylaxis with repeat dosing observed in preclinical GHRH analog studies.
⚠️ CJC-1295 (no DAC) is not FDA-approved. It is a research compound only. No completed Phase 3 clinical trials. Not for human therapeutic use.
Compound Information
Technical specifications for CJC-1295 (Modified GRF 1-29, no DAC)
| Also Known As | Modified GRF(1-29), Mod GRF, CJC-1295 no DAC |
| Type | Synthetic GHRH analog — no albumin-binding modification |
| CAS Number | 863288-34-0 (base peptide, no DAC) |
| Molecular Weight | 3,367.9 g/mol |
| Amino Acids | 29 (GHRH 1–29 analog, 4 substitutions) |
| Key Substitutions | Ala²→Aib, Arg8→Gln, Ala15→Aib, Leu27→Leu (various sources vary) |
| Plasma Half-Life | ~20–30 minutes |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for up to 24 months |
| Storage (reconstituted) | 2–8°C, use within 30 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
Frequently Asked Questions
Common questions about CJC-1295 (no DAC) research
CJC-1295 without DAC — also called Modified GRF(1-29) or Mod GRF — is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH). It incorporates four amino acid substitutions that resist DPP-IV protease cleavage, extending the half-life from ~7 minutes (native GHRH) to approximately 20–30 minutes. Unlike CJC-1295 DAC, it does not contain the albumin-binding Drug Affinity Complex (DAC) modification, so it produces pulsatile rather than sustained GH stimulation.
The sole structural difference is the presence or absence of the Drug Affinity Complex (DAC) — a maleimidopropionic acid group on Lys8. Without DAC: half-life ~30 minutes, produces discrete GH pulses, requires multiple daily administrations for sustained effects, mirrors physiological GH pulse patterns. With DAC: half-life 5.8–8.1 days via albumin binding, produces sustained GH/IGF-1 elevation, enables once-weekly dosing in research protocols.
Endogenous growth hormone is secreted in 6–12 discrete pulses per day from the anterior pituitary, primarily during slow-wave sleep. Pulsatile GH secretion is associated with differential downstream effects compared to continuous exposure — affecting IGF-1 production, receptor sensitivity, and anabolic signaling differently. CJC-1295 without DAC's short half-life makes it useful for research protocols that need to preserve or study this physiological pulsatile pattern, rather than maintaining continuous elevated GH.
CJC-1295 (no DAC) activates GHRH receptors (GHRH-R) on pituitary somatotrophs, while ipamorelin activates Growth Hormone Secretagogue Receptor 1a (GHSR-1a). These are distinct receptor systems that work through complementary intracellular pathways. When both pathways are activated simultaneously, GH pulse amplitude is enhanced above what either compound produces alone. This synergistic mechanism is the scientific rationale behind the CJC-1295/Ipamorelin research blend.
No. CJC-1295 without DAC is not FDA-approved for any indication. It is a research compound available for in vitro laboratory use only. No standalone Phase 3 clinical trials have been completed for this specific form. It is not intended for human therapeutic use.
Lyophilized (powder) form should be stored at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 30 days. Avoid repeated freeze-thaw cycles and protect from light. The absence of the DAC modification means the peptide is more susceptible to DPP-IV degradation once in solution — use reconstituted material promptly.
Sources & References
PubMed
Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults
2006
PubMed
GHRH analog sermorelin and modified GRF pharmacodynamic comparison — protease resistance and half-life
2003
⚠️ For research use only. Not for human or veterinary therapeutic use. These statements have not been evaluated by the Food and Drug Administration.
Published research on this compound is available through PubMed and other scientific databases.
Certificate of Analysis
| Analysis Date: | Available on request |
| Lot Number: | Batch-specific |
| Purity: | >99% (HPLC) |
Third-Party Testing
- ✓ Identity verification (Mass Spectrometry)
- ✓ Purity analysis (HPLC)
- ✓ Sterility testing
- ✓ Endotoxin screening
Storage Conditions
- Lyophilized: Store at -20°C, protected from light
- Reconstituted: Store at 2-8°C, use within 30 days
- Stability: 24 months from manufacture date when stored properly
Handling Guidelines
- Use sterile technique when reconstituting
- Allow vial to reach room temperature before opening
- Reconstitute with bacteriostatic water or sterile saline
- Avoid repeated freeze-thaw cycles
RESEARCH INSIGHTS
3D Structure
CJC-1295
This compound has been extensively studied in peer-reviewed literature. Eon Peptides provides this product exclusively for legitimate in-vitro research and analytical applications.
- • High-purity research compound
- • Full analytical documentation included
- • Third-party verification available
PRODUCT SPECIFICATIONS
LOT DATA
| Lot Number | Assigned on shipment |
| Verified Purity | >99% |
| Quantity | 5mg |
MOLECULAR DATA
| Molecular Formula | Available on request |
| Form | Lyophilized Powder |
| Appearance | White to off-white powder |
